Open Innovation Portal
DNDi’s mission is to develop safe, effective, and affordable new treatments for patients suffering from neglected diseases and to ensure equitable access to these. Encouraging innovation is one way that we do this. Dedicated to fostering advancement in global health by supporting the research community in the field of neglected diseases, we have taken steps to disseminate the scientific knowledge gained through research projects with our many partners.This will be done through both the more traditional means of scientific articles, and less traditional means, notably by sharing data on chemical compounds in the public domain.
The data we make available is the fruit of collaboration with our partners and is part of our constant effort to render accessible to entire scientific community, whenever possible:
- Both positive and negative research results, as negative results can offer a wealth of information, allow for new research approaches to the same series with potentially different outcomes, and eliminate duplication of efforts
- Data that DNDi and its partners have willfully agreed to place in the public domain, free of any and all IP constraints.
For more information: “Striving for increasingly open innovation models”
Antiprotozoal activity profiling of approved drugs: a starting point toward drug repositioning
A set of 100 registered drugs with drug repositioning potential for neglected tropical diseases was assembled. The compound collection was systematically screened against protozoan parasites, T. b. rhodesiense, L. donovani, T. cruzi and P. falciparum.
Guides to free computational chemistry tools for drug discovery
AMG Consultants has produced guides to share free solutions to common problems faced by medicinal and computational chemists in not-for-profit research.
The NTD Drug Discovery Booster
The NTD Drug Discovery Booster aims to speed up the process and cut the cost of finding new treatments for Leishmaniasis and Chagas Disease. The project brings together DNDi and five pharmaceutical companies: Eisai Co Ltd, Shionogi & Co Ltd, Takeda Pharmaceutical Ltd, AstraZeneca plc, and Celgene Corporation.
The Pathogen Box
The Pathogen Box will contain ~400 diverse, drug-like molecules active against neglected diseases of interest and will be available free of charge at the end of 2015.
Two series of fenarimols for the treatment of Chagas disease
This second release includes data on a further 84 compounds from the two more advanced series of fenarimols which include the preclinical candidates EPL-BS0967 and EPL-BS1246, both of which are T.cruzi CYP51 inhibitors.
Source data from neglected disease R&D pipeline review
In late 2013, DNDi and colleagues published an analysis in The Lancet Global Health looking at the R&D landscape over the last decade in terms of new therapeutic products for 49 so-called neglected diseases. In the hope of promoting further research, we have created a public data-sharing page with full datasets from the study freely accessible to all.
Screening and lead optimization of new compounds for Chagas disease (>300,000 compounds)
We have evaluated multiple hits generated from a high-throughput screen of over 300,000 compounds to identify inhibitors of T. cruzi. These studies have resulted in the discovery of two novel series currently in lead optimisation.
iNTRODB – an Integrated system for searching drug-target proteins from parasitic protozoa genomes
iNTRODB is an integrated system for searching drug-target proteins from parasitic protozoa genomes that cause neglected tropical diseases, including leishmaniasis, Chagas’ disease and human African trypanosomiasis
Screening identifies new compounds for HAT
Identification of compounds against Trypanosoma brucei brucei BS427 by high-throughput screening of whole parasites (87,926 compounds)
DNDi Screening of the MMV Open Access Malaria Box for HAT, VL, and Chagas disease
Screening of the MMV Open Access Malaria Box in the search for new drugs against Human African Trypanosomiasis (HAT), visceral leishmaniasis and Chagas disease
SCYNEXIS Inc. as part of the DNDi HAT Lead Optimization Consortium
Screening and optimization of specific chemical series against human African Trypanosomiasis (HAT): 4926 compounds
Optimization of fenarimol series for the treatment of Chagas disease: 751 compounds
For more information: firstname.lastname@example.org